Science, Innovation, And Emerging Markets: Reshaping The Future Of The .

Transcription

The 14th SAPA-NE Annual Conference 2012Science, Innovation, and Emerging Markets:Reshaping the Future of the Biopharma IndustrySaturday, June 16th, 2012Wong Auditorium, Tang Center, Building E51, Sloan School of ManagementMassachusetts Institute of Technology, Cambridge, MA 02139Organizer: SAPA-NE www.SAPA-NEweb.org

Conference OrganizersConference Chair:Liqiang Derek Tou, MD, PhD, MBA SAPA-NE, President-Elect, Millennium/TakedaCo-Chairs/Moderators:Min Chen, PhDHuo Li, PhDXiaotian Zhong, PhDQingcong Lin, PhDJohnny Yang, PhDXiang Niu, MBA, M.S.Jiali Chen, M.D. MBAJiang Long, PhDJie Zhao, M.D., PhDGuiqing Liang, PhDWenlai Zhou, Ph.DSAPA-NE, President, NovartisSAPA-NE, Immediate Past President, Biogen-IdecSAPA-NE, Past President, SAPA Secretary General, PfizerSAPA-NE, Secretary General, PfizerSAPA-NE, Executive Committee member, Millennium/TakedaSAPA-NE, Executive Committee member, Avecia BiotechSAPA-NE, Executive Committee member, PfizerSAPA-NE, Executive Committee member, Enanta PharmaSAPA-NE, Executive Committee member, MGHSAPA-NE, Executive Committee member, , NovartisSAPA-NE, Executive Committee member, NovartisOrganizing Committee Members:Daming Gou, PhDBingli Ma, M.D.Dapeng Chen, PhDDongli Chen, PhDWeijun Ma, MBA, M.S.Wenge Wang, PhDJun Zhao, M.S.Tianxiao Sun, PhDJinhua Zhang, M.S.Yi (Ian) Liu, J.D. PhDJiaquan Wu, PhDYide Jiang, PhDYoudan (Kelsey) Wang, M.S.Gaozhong Zhu, PhDZhiwei Pan, PhDYuxun Wang, M.D. PhDLan Yang, M.S.Huamao Mark Lin, PhDJenny Li, M.S.Yongchun Shen, PhDHuimin Chen, PhDKen Li, MBA, M.S.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgSAPA, Board of Director member, Johnson Mattey PharmaSAPA, Board of Director member, Millennium/TakedaSAPA-NE, Executive Committee member, NovartisSAPA-NE, Executive Committee member, Epix PharmaSAPA-NE, Executive Committee member, PfizerSAPA-NE, Executive Committee member, PfizerSAPA-NE, Executive Committee member, MerckSAPA-NE, Executive Committee member, MerckSAPA-NE, Executive Committee member, GenzymeSAPA-NE, Executive Committee member, Finnegan, LLPSAPA-NE, Executive Committee member, AstraZenecaSAPA-NE, Executive Committee member, Genzyme/AventisSAPA-NE, Executive Committee member, Brown UniversitySAPA-NE, Executive Committee member, Shire HGTSAPA-NE, Executive Committee member, Shire HGTSAPA-NE, Executive Committee member, Metamark GeneticsSAPA-NE, Executive Committee member, Genzyme/SanofiSAPA-NE, Advisory Committee member, Millennium/TakedaSAPA-NE, Advisory Committee member, PfizerSAPA-NE, Advisory Committee member, Eisai ResearchSAPA-NE, Advisory Committee member, GSKSAPA-NE, Advisory Committee member, Mingxin Growth Fund-1-

Greetings from the Conference ChairDear distinguished speakers, ladies and gentlemen, SAPA Members,On behalf of the Sino-American Pharmaceutical Professionals Association-NewEngland (SAPA-NE), I am pleased to welcome you to the 14th SAPA-NE AnnualConference. The theme of this special event is "Science, Innovation, andEmerging Markets: Reshaping the Future of the Biopharma Industry".The pharmaceutical landscape is rapidly changing on a global scale. Bigbiopharma is facing unprecedented challenges due to various factors, such aspatent expiration of blockbuster drugs, higher R&D cost, and economic downturn,therefore it is increasingly chasing opportunities in new emerging markets like China and India; In the otherpart of the world, with two decades of economic growth and a population of 1.3 billion people, technicallysavvy returnees, the increased investment by the Chinese government, and improved intellectual propertyenvironment, innovative drug R&D is on the rise in China. Novel drugs completely developed by Chinesecompanies are likely to be marketed worldwide in the near future. Multinational pharmaceutical companiesare actively setting R&D centers in China to complement their existing R&D capabilities, and facilitatecollaborations with scientists across Western counties and emerging market. The conference serves as aplatform for biopharma industry executives, successful entrepreneurs, investors and many other experts tointeractively explore and address the opportunities and challenges.Together, we can bridge. Thanks to the great efforts of our conference committee and the support of ourdistinguished speakers and panelists, we have the privilege to present you with a wonderful program thatcaptures those critical issues. In the section “Science, innovation in the global market”, Dr. Rosenblatt(Merck), Dr. JC Gutierrez-Ramos (Pfizer) and Dr. Karin Briner (Novartis) will discuss new R&D strategiesincluding China opportunities for the industry. In “Business development in the emerging market”, Ms. AnnaProtopapas (Millennium/Takeda), Dr. Peng Wang (Simcere) and Dr. Donald Bergstrom (Sanofi) will focusmore on the global business strategy and share their visions on how big pharma can break into the Chinesemarket. This year we also put lots of emphasis on the two panel forums covering how big pharma can seizethe China opportunity and how Chinese returnee entrepreneurs can reshape the future of China.Furthermore, what will make this annual meeting special is that Zhejiang afternoon Overseas High-levelTalents Exchange and Cooperation Events will happen at Walker MIT Morss Hall. The conference will befollowed by a dinner banquet “Zhejiang night” for you to enjoy the excellent networking opportunity, and ourdinner keynote speaker Babson Professor Bob Caspe and Dr. Yingxiang Wang will share their excitingentrepreneurial stories.Finally, our thanks go to the sponsors listed in this program, whose generosity makes this event possible. Iwould also like to invite you all to join and support SAPA, a non-profit organization founded in 1993. Itsmission is to serve its members and to promote the pharmaceutical sciences, the biomedical andbiotechnological communities, and public health interests. SAPA has more than 5,000 members in the US,and New England itself attracts more than 900 professionals. For more details, please visit our websitewww.SAPA-NEweb.org.I am very excited to have you participating in our 2012 annual conference, and hope that you enjoy thekeynote presentation, panel discussion, exhibition, and great networking opportunities.Sincerely yours,Liqiang Derek Tou , MD, PhD, MBA.SAPA-NE 2012 Conference ChairSAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.org-2-

Conference Program8:00 – 8:50Registration* and BreakfastOpening Remarks8:50 – 9:00Liqiang Derek Tou, MD, PhD, MBASAPA-NE 14th Annual Conference Chair, SAPA-NE President-ElectSession 1: Science and Innovation in the global MarketChairs: Drs. Liqiang Derek Tou, Xiaotian Zhong & Guiqing LiangMichael Rosenblatt, MD, PhD Executive Vice President and Chief Medical9:00 – 9:30Officer at Merck“How do We Bring the Best of Medicine to all People”JC Gutierrez-Ramos PhDSVP/CSO, Pfizer WRD9:30 – 10:00“Innovation and Connectivity in BioPharmaceutical Research andDevelopment”10:00 –10:30Dr. Karin Briner PhD Vice President, Head of Global Discovery Chemistry,Novartis"Diverse Approaches to Drug Discovery - Keeping the Patient and UnmetMedical Need in Focus"Coffee Break and ExhibitionSession 2: Panel Forum I: Seizing the China opportunities in the emergingmarketChairs: Dr. Gaurab Bhardwaj, Jiali Chen, long Jiang11:00 –12:30Panelist:Ajay Sharma, PhD, MBA, Director, Business Development and Sales, FrontageLaboratoriesAlan Wong, VP of Manufacturing Technologies, Livzon MabPharmaFireli Alonso-Caplen, PhD, Senior Director of biopharmaceutical and vaccineoutsourcing, PfizerGeorge Li, MBA, Deputy CEO of Wuxi Bridgebio International Corporation.Jean Qiu, PhD, Founder and President, Nexcelom BioscienceKen Li, MBA, Partner, Mingxin China Growth FundLaura Sailor, VP Sales and Marketing at Emerald BioLisan Parker, PhD, Senior business manager, GenScriptLixin Yu, Executive Director, Laviana CorporationMeihan Wu, General manager of Beijing Zhongguancun Life Science Park Biomedical incubator Co., LtdYufang Shao, PhD, Vice President, Novoprotein Scientific INCLunch and ExhibitionSAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.org-3-

Session 3: Business Development in the Emerging MarketChairs: Drs. Johnny Yang, Qingcong Lin, Wenlai Zhou1:15 – 1:451:45 – 2:152:15 – 2:45Anna Protopapas, MBA, EVP, Global Business Development, TakedaPharmaceuticals“Takeda Pharmaceuticals: Extending their Global Reach "Peng Wang, PhD, Vice President, Chief Scientific Officer , Simcere“Challenges and opportunities for pharmaceutical R&D in China”Donald A. Bergstrom MD, PhD, Associate VP and Global Head, Translationaland Experimental Medicine, Sanofi Oncology“Building a global translational medicine organization: executingtranslational research in emerging markets"Coffee Break and Exhibition2:45 – 3:003: 00– 4:00Move to Morss HallZhejiang Overseas High-level Talents Exchange and Cooperation EventsSession 4: Panel Forum II: Innovative drug R&D in China (Morss Hall)Chairs: Mr. Xiang Niu, Dr. Gaurab Bhardwaj, Jiali Chen4:00 – 5:30Panelist:Chun-lin Chen, PhD, CEO, MedicilonDongxiao Feng, PhD, Executive Director, Luye Pharma.Chongqin Yi, PhD, President, PKU Care Pharmaceutical R&D CenterJason (Gang) Jin, PhD, CEO of ShanghaiBio and VP of Shanghai BiochipJasmine (Jisong) Cui, PhD, Chief Scientific Officer, BioDuro, PPDLianshan Zhang, PhD, President of Global R&D, Jiangsu HengruiPatrick Y. Lu, PhD, President & CEO, SirnaomicsSteve Sun, PhD, Chairman and CEO of GENEWIZ Inc.Yinxiang Wang, PhD, CEO&CSO, Zhejiang Beta Pharma Inc.SAPA-NE 14th Annual Conference Dinner Reception(ticket required)Chair: Liqiang Derek Tou, Huo Li, Jie Zhao6:00– 9:30Place: MIT Faculty Club6:00-6:306:30-7:00Open Bar and NetworkingWelcome Remarks:Min Chen, PhD, SAPA-NE President/ Leland Cheng, CambridgeCouncilor / Zhejiang governor/ Zhejiang Future Industry Park7:00-7:30 Plate DinnerSAPA-NE Service Award PresentationHigh School Excellence Scholarship Award Presentation7:30-9:00 Dinner Keynote:Bob Caspe Founder, International Entrepreneurship Center, Professorat Babson CollegeYinxiang Wang, PhD, CEO&CSO, Zhejiang Beta Pharma Inc.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.org-4-

About the SpeakersSession 1: Science and Innovation in the global MarketDr. Michael Rosenblatt, MD, PhDExecutive Vice President and Chief MedicalOfficer, MerckScientist, educator,hospital and globalhealthcare companyexecutive, MichaelRosenblatt, M.D., isExecutiveVicePresident and ChiefMedical Officer atMerck.Herepresents the voiceof the patient andmedicine inside Merck and is the company’sprimary external advocate on medical issues.Dr. Rosenblatt previously was Dean of TuftsUniversity School of Medicine and the George R.Minot Professor of Medicine at Harvard MedicalSchool. He served as the President of Beth IsraelDeaconess Medical Center. He was also Directorof the Harvard-MIT Division of Health Sciencesand Technology.Prior to these leadership positions, he was SeniorVice President for Research at Merck where heco-led the worldwide development team foralendronate(FOSAMAX ),Merck'sbisphosphonate for osteoporosis and bonedisorders. From 1981 to 1984, he served asChief of the Endocrine Unit at the MassachusettsGeneral Hospital.He is the recipient of the Fuller Albright Award forhis work on parathyroid hormone and the Vincentdu Vigneaud Award in peptide chemistry andbiology, and the Chairman’s Award from Merck.Committed to innovation, he has served on theboard of directors and scientific advisory boardsof several biotechnology companies.Dr.Rosenblatt was elected to the American SocietySAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgof Clinical Investigation and the Association ofAmerican Physicians, is a fellow of the AmericanAssociation for the Advancement of Science andthe American College of Physicians, and servedas the president of the American Society of Boneand Mineral Research.He has served as a consultant to the U.S.President's Council of Advisors on Science andTechnology.He received his undergraduate degree summacum laude from Columbia University and his M.D.magna cum laude from Harvard Medical School.He trained in internal medicine and endocrinologyat the Massachusetts General Hospital.“How do We Bring the Best of Medicine to allPeople”The biopharmaceutical industry is the mostresearch-intensive industry in the world, routinelyinvesting 20 percent or more of revenues in R&D.But scientific innovation is an increasing struggle– technically, economically and even emotionally.How can we sustain today’s quality of innovationdespite the growing challenges? Dr. MichaelRosenblatt, Executive Vice President and ChiefMedical Officer, Merck, will discuss developmentson the new frontier of innovation – collaboration.Whether inside the research laboratory or on thefront lines with patients in local communities,novel models for collaboration are needed to helpaddress the world’s most pressing health needs.Dr. Rosenblatt will explore new kinds of alliancesthat are helping to fuel health innovation. He willexplore examples ranging from research institutesand venture funds to pre-competitive technologyalliances to partnerships involving differentcompanies and multiple sectors – all of whichunderscore the value of collaboration.-5-

Session 1: Science and Innovation in the global MarketJC Gutierrez-Ramos PhDSenior Vice President, Head ofBioTherapeutics Research & DevelopmentPfizer IncJose-Carlos“JC”Gutierrez-Ramos,PhD, is Senior VicePresident and HeadofBioTherapeuticsResearch&Development, withinPfizerWorldwideResearch&Development. JC ispassionate about theearly and iterativeuse of experimentalmedicine approachesin discovery research,the continuous focus on scientific innovation andmedical differentiation during drug discovery, andthe “entrepreneurialization” of big pharmaresearch groups.Prior to joining Pfizer, JC was Senior VicePresident and Head of the Immuno-inflammationCenter for Drug Discovery (iiCEDD) at GlaxoSmith Kline. JC built the iiCEDD as a globalgroup of “drug hunters” that included biologists,chemists, pharmacologists, protein scientists,clinicians and business developers who wereresponsible for drug discovery and developmentthrough Phase IIa (Proof of Concept). Chiefachievements in the formation of the iiCEDDincluded entrepreneurial organizational andSAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgfunding structure, the talent recruitment andidentification of innovative discovery areas tofocus on, which were poised for medicaldifferentiation. The iiCEDD pipeline had asignificant external component with 50 percent ofits pipeline and activities achieved throughexternal partnerships with biotech companies,academia and contract research organizations.Prior to GSK Jose-Carlos served as Site Head andChief Scientific Officer (CSO) at AMGEN MountainView. Previous to the AMGEN acquisition of Avidia,he was the Senior Vice President of R&D, wherehe led a significant effort of novel proteintherapeutics for autoimmune disease. Before hisAVIDIA appointment, he served as CSO ofPeptimmune Inc. in Cambridge, MA, where he wasresponsible for the development of peptide basedtherapeutics for autoimmune disease, mune, JC served as Vice President,Inflammation at Millennium Pharmaceuticals,where he was responsible for advancing preclinicalcandidates in Inflammation & Immunology tohuman trials and advancing compounds (smallmolecules and antibodies) from discovery throughclinical development.“Innovation and Connectivity inBioPharmaceutical Research andDevelopment”-6-

Session 1: Science and Innovation in the global MarketKarin Briner, PhDVice President, Global Head of DiscoveryChemistry, Novartis Institutes for BioMedicalResearch, CambridgeDr. Briner obtained her BScinChemistryandBiochemistry and her PhD inOrganic Chemistry from theUniversity of Zurich. She didNSF and NIH postdoctoralstudies at Indiana University.In 1995, she joined Eli Lilly &Co. in Indianapolis as Senior Organic Chemist andbecame soon thereafter a project leader in theNeuroscience Research area.From 2000 to 2010, she was a member of theDiscovery Chemistry management team withincreasing responsibilities, starting as MedicinalChemistry Director in Neuroscience and EndocrineResearch, later as Executive Director for Global LeadOptimization Chemistry and for Discovery Chemistryat the Lilly European Sites. Throughout this time upto 2007, she maintained her own research laboratorycontributing new portfolio projects and deliveringmolecules into the clinic.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgFrom 2007 to 2010, she was ManagingDirector and Research Head of the LillyResearch Centre, UK, with a focus inNeuroscience Research.In 2010, she became Vice President ofTranslational Sciences and Technologies,located in Indianapolis, with responsibilities forbiomarker discovery research across alltherapeutic areas, centralized in vitroscreening, and structural biology.In June 2011, Karin joined Novartis as GlobalHead of Discovery Chemistry.“Drug Discovery Challenges andOpportunities – Keeping the Focus on thePatient and Unmet Medical Need”An overview of some challenges in drugdiscovery and our attempts to address themwill be given.Some specific projects will be discussed,highlighting the exciting opportunities createdthrough science and technology innovationsguided by patient needs-7-

Session 3: Business Development in the Emerging MarketAnna Protopapas, MBAEVP, Global Business Development TakedaPharmaceuticalsAnna Protopapas is theExecutive Vice PresidentofGlobalBusinessDevelopment at TakedaPharmaceuticalsresponsible for licensing,acquisitions, alliance andlicensee management aswell as venture investing.She is a member ofTakeda’s executive team and a corporate officer.Since assuming the role, she has helped buildTakeda’s global capabilities in businessdevelopment and led the strategic initiative thatresulted in the 9.6 billion euro acquisition ofNycomed, a transaction that transformed Takedainto a top pharmaceutical company with a globalfootprint.Prior to assuming this role, she was responsiblefor leading the strategy and businessdevelopment effort at Millennium Pharmaceuticalswere she was instrumental at driving variousstrategic transactions that transformed thecompany from an early stage technologycompany to a fully integrated oncology leader.She led the partnership discussions with TakedaPharmaceuticals that ultimately resulted in theacquisition of Millennium by Takeda for 8.8billion. Following the acquisition, she led thesuccessfulintegrationbetweenthetwocompanies that established Millennium asTakeda’s oncology center of excellence.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgPrior to Millennium, Anna held various positionsoutside the life science industry in engineering,global marketing and business development. Sheholds a BSE in Chemical Engineering fromPrinceton University, Masters in Engineering fromthe Massachusetts Institute of Technology and anMBA from the Stanford Business School. She is anative of Cyprus and now lives in Boston with herhusband and three children.“Takeda Pharmaceuticals: Extending their GlobalReach”Takeda Pharmaceuticals,Japan’sleadingpharmaceutical company, has a long history ofbringing innovative medicines to patients aroundthe world. The company is accelerating its growthto increase its presence in new and emergingmarkets, and become a leading globalpharmaceutical player. In recent years Takedahas acquired Millennium Pharmaceuticals whichhelped them strengthen their presence in the allimportant oncology market, and Nycomed whichhelped Takeda gain access to many emergingmarkets. Currently the company spans acrossfive geographies and over 70 global markets.Takeda has had a long standing commitment tobringing innovative products to the Chinesemarket. That effort has been strengthen throughthe acquisition of Nycomed and throughcontinued investment by Takeda to continue tobuild capabilities and fuel growth.During herpresentation, Ms. Protopapas will provide anoverviewofTakeda’sglobalbusinessdevelopment strategy, while offering an insightinto the opportunities presented in China.-8-

Session 3: Business Development in the Emerging MarketPeng Wang, PhDVice President, Chief Scientific OfficerSimcereDr. Peng Wang, ,iscurrentlyChiefScientific Officer ofSimcerePharmaceuticalsGroup, a leadingChinesepharmaceuticalcompany headquartered in Nanjing, China(simcere.com; “SCR” at NYSE). Prior to joiningSimcere, Dr. Wang was with WuXi PharmaTech(wuxiapptec.com; “WX” at NYSE), a leadingpharmaceutical CRO in China, as Vice Presidentof Discovery Biology in 2008-2009. Prior to joiningWuXi PharmaTech, Dr. Wang worked ondiscovery through early clinical development forSchering-Plough in New Jersey, USA for 18years. Dr. Wang has made significantcontributions to discovery and early developmentof 16 drug candidates in US and China, and toSAPA-NE 14th Annual Conference nies. Dr. Wang has published numerouspapers as corresponding author in leadingscientific journals such as Proc. Natl. Acad. Sci.USA, J. Biol. Chem., Blood, J. Immunol., Am. J.Respir. Crit. Care Med., Mol. Pharmacol.,Biochem. J. etc. Dr. Wang received his PhD inBiochemistry from the University of Tokyo, andhis B.S. in Medicinal Chemistry from the ChinaPharmaceutical University.Challenges and opportunities forpharmaceutical R&D in ChinaAlthough in US/Europe the industry R&Dexpenditures have now flattened, in China theR&D boom is just starting. There are uniquechallenges and opportunities for R&D in China,which will be discussed in this presentation. Inaddition, our new approaches aimed at improvingR&D productivity will be discussed as well.-9-

Session 3: Business Development in the Emerging MarketDonald A. Bergstrom MD PhDAssociate VP and Global Head,Translational and Experimental MedicineSanofi OncologyDonaldBergstromjoined Sanofi OncologyinMay2010asAssociateVicePresident and GlobalHead of TranslationalandExperimentalMedicine, where heleadsateamoflaboratory and clinicalscientists who opment to ultimately improve the care ofpatients with cancer. The group is dedicated tomolecular understanding of pre-clinical models onwhich decisions to pursue clinical development arebased, and then designing clinical researchstrategies to most closely mimic the successfulpre-clinical program. Prior to joining Sanofi,Bergstrom spent 6 years at Merck Research labswhere he held roles of increasing responsibility inthe Clinical Molecular Profiling, Oncology ClinicalResearch and Experimental Medicine Oncologygroups. Prior to joining industry he completed hisMD degree at the University of Washington and hisPhD and post-doctoral training at the FredSAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgHutchinson Cancer Research Center, both inSeattle, WA. He was a resident in ClinicalPathology at the University of Washington.“Building a global translational medicineorganization: executing translationalresearch in emerging markets”Novel clinical trial endpoints, including molecularimaging and genomics, hold great promise for thedevelopment or more effective cancer drugs.Traditionally these studies have been confined toeither early phase clinical trials or translationalsub-studies embedded into global late phase trials.In either case global pharmaceutical companieshave typically only pursued these complex studiesat a relatively small number of well-establishedacademic medical centers, predominantly in NorthAmerica and Western Europe. As globalpharmaceutical companies increase their focus onemerging markets for the development of bothglobal and regional products, they have had tofocus on building global translational medicinecapabilities. This talk will present one approach tobuilding such an organization, pairing globalsubject matter expertise within the pharmaceuticalcompany with external capabilities within theemerging market.- 10 -

Session 2: Panel Forum I: Seizing the China Opportunities in theEmerging MarketGaurab Bhardwaj, PhD,Endowed Chair Professor, Babson CollegeAssociate Professor andThe Louis J. Lavigne, Jr.Family Endowed TermChair in Strategy ecutiveEducationBabsonCollege,Wellesley, MA.Gaurab’sresearch,teaching, facilitation, speaking, and consultingexpertise are in strategy, innovation, andentrepreneurship in science-based althcare,andchemicals. The National Science Foundation andthe Eleutherian Mills – Hagley Foundation havefunded his on-going research program on the“Management of Distant Returns” where he isinvestigating how people make decisions that arehighly uncertain and ambiguous, and whoseoutcomes take shape over many years. Hisresearch, writing, and professional presentationsare on discovery processes of corporatescientists, science and strategy for achievinglong-term corporate growth, and anticipatoryinnovation and entrepreneurship. His work hasinvolvedscientistsandmanagersinpharmaceutical, agriculture, and biotechnologybusinesses. He is currently working, along withthe founder of a biotechnology company, on anew way to innovate that anticipates markets.Gaurab’s research has been published in thejournals Management Science, Expert Opinion onDrug Discovery, Chemical Heritage, and as achapter in the book Innovating Strategy Process.He has written for BioExecutive International andBabson Insight and his work has been covered inEffective Executive.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgGaurab is the faculty director of Babson’sexecutive education program “Bio-Pharma:Mastering the Business of Science” for biopharma scientists and managers. In addition toteaching competition and strategy in this program,he teaches in the MBA program and has taught incustom programs for Eli Lilly, Biogen Idec, DanaFarber Cancer Institute, EMC, and LucentTechnologies. Gaurab has a PhD in strategy andmanagement from the University of Pittsburghand an MBA from Northeastern University.Ajay Sharma, PhD, MBA, Director, . Ajay Sharma is theDirectorofBusinessDevelopment and Sales forFrontage,aglobalpharmaceuticalresearchand development companywith GMP labs and clinicalresearch facilities in the U.S.andChina.Frontageprovides a broad range of drug lopment, preclinical, clinical research, andregulatory consulting.Dr. Sharma obtained his PhD in MolecularBiology from University of Southern California andan MBA from Rutgers University, NJ. Dr. Sharmahas over 20 years of R&D, Management andBusiness Development experience in the broadlife sciences industry including Drug Discoveryand Development. He is experienced in productpositioning for commercialization, ement, and technology evaluation. Prior tojoining Frontage, Dr. Sharma held a variety of Dr.Sharma held a variety of management positionsin pharmaceutical and service opment at Caliper Life Sciences; Director- 11 -

R&D, Molecular Biology at Millipore Corp.; andDirector, R&D at Bionaut Pharmaceuticals. As asenior scientist at Baxter International (NextranInc) Dr. Sharma worked on a Human Bloodsubstitute and conducted research in the field ofXenotransplantation.Dr. Sharma holds multiple US patents andpublications in molecular and cellular biology,oncology, transgenics, glycosylation, proteinexpression and immunology.Alan Wong, VP of ManufacturingTechnologies, Livzon MabPharmaAlan has a MBA in Finance(Le Moyne College) and aBS in Chemical Engineering(University of Rochester). HehasOver23years’experienceinbiopharmaceutical industrywith extensive experience turing, global supplychain,cold chain management, project management,strategy development, strategic/financial analysis,start up , scale up, process implementation. Experience also includes, but isnot limited to, international operations, tical companies Alan has workedfor include Livzon MabPharm, Inc., Regeneron,Biogen-Idec, Wyeth (Pfizer), Millennium, BristolMyer Squibb, Schering-Plough (Merck) andGenex. Accomplishments achieved include, butnot limited to, helping design a 170,000 sq ftantibody facility for GMP ngprocesses, improving operations efficiency,improving strategic partners’ working relationship,cost-saving for companies ranging from 50,000– over 1 million annually.SAPA-NE 14th Annual Conference 2012http://www.sapa-NEweb.orgFirelli Alonso-Caplen, PhD, Senior Director ofbiopharmaceutical and vaccine outsourcing,PfizerDr. Firelli Alonso-Caplen is aSenior Director at Pfizer, Inc.She heads the ofWorldwideResearch andDevelopment. Fi has more than 27 years ofcombined experience in research, development,and cGMP production of biological products andvaccines, and more than 7 years experience inoutsourcing, project / contract management, andtechnology transfer to qualified third parties. Herareas of expertise include viral vectors andvaccine development, biotherapeutics andvaccine process development and cGMPproduction, project management, technologytransfer, outsourcing, and budget and operations.She obtained her PhD in Microbiology from theUniversity of Alabama in Birmingham, followed bypostdoctoral research at the U.S. Army MedicalResearch Institute for Infectious Diseases, SloanKett

Xiang Niu, MBA, M.S. SAPA-NE, Executive Committee member, Avecia Biotech . Jiali Chen, M.D. MBA SAPA-NE, Executive Committee member, Pfizer . dinner keynote speaker Babson Professor Bob Caspe and Dr. Yingxiang Wang will share their exciting entrepreneurial stories. Finally, our thanks go tothe sponsors listed in this program, whose generosity .